Slide 1: Annual Financial Statements FY/2017 Conference Call
aap Implantate AG Annual Financial Statements FY/2017 Conference Call Bruke Seyoum Alemu, CEO Marek Hahn, CFO Berlin, April 4, 2018
Slide 2: Safe Harbor Statement
Safe Harbor Statement Our publication may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual
Slide 3: Key results and progress FY/2017 (1/3)
Key results and progress FY/2017 (1/3) ➢ Trauma sales ▪ Successful first year as a pure player in trauma with y-o-y trauma sales growth of 20% to EUR 10.6 million (FY/2016: EUR 8.9 million) ➢ Sales and Earnings ▪ Sales with EUR 10.9 million (+4% vs. FY/2016) in line with guidance (EUR 10.0 million t
Slide 4: Key results and progress FY/2017 (2/3)
Key results and progress FY/2017 (2/3) ➢ LOQTEQ® ▪ Successful completion of development activities of LOQTEQ® VA foot and ankle system and other polyaxial LOQTEQ® systems ➢ Silver coating technology* ▪ aap development team reinforced with experienced specialist and management staff from leading glob
Slide 5: Key results and progress FY/2017 (3/3)
Key results and progress FY/2017 (3/3) Implementation of strategic imperatives Products Customers Accelerating Value-based Innovation Enhancing Enhancing Market Market Access Access ➢ LOQTEQ®: Completion of LOQTEQ® portfolio with a ➢ ➢ Established Established countries: countries: Focus Focus onon D
Slide 6: Financial Figures FY/2017
Financial Figures FY/2017 (in KEUR) Sales FY/2017 FY/2016 Change Trauma 10,648 8,877 +20% Germany 2,428 2,352 +3% North America 3,071 2,436 +26% North America Distributors 2,491 1,464 +70% North America Global Partners 580 972 -40% International 5,149 4,089 +26% Other (mainly discontinued activities
Slide 7: Highlights FY/2017 (Balance Sheet)
Highlights FY/2017 (Balance Sheet) ➢ Total assets 12/31/2017: EUR 50.5 million (12/31/2016: EUR 63.9 million) -21% ▪ Non-current assets: Change EUR -0.4 million Capitalized development costs: EUR +0.7 million; share of intangible assets in total assets: 23% Tangible assets: EUR -0.4 million
Slide 8: Highlights FY/2017 (Cash Flow)
Highlights FY/2017 (Cash Flow) ➢ Operating Cash Flow FY/2017: EUR -5.4 million (FY/2016: EUR -7.2 million) ▪ Improved operating result ▪ Positive contribution from working capital reduction ➢ Investing Cash Flow FY/2017 : EUR -1.5 million (FY/2016: EUR +29.8 million) ▪ Investments in FY/2017: EUR 0.
Slide 9: Management Agenda 2018
Management Agenda 2018 Implementation of strategic imperatives Products Customers Accelerating Value-based Innovation Enhancing Enhancing Market Market Access Access ➢ Silver coating technology – Application on LOQTEQ®: ➢ ➢ Established Established countries: countries: Focus Focus on on DACH, Wester
Slide 10: Silver Coating Technology – Update
Silver Coating Technology – Update Substantial progress regarding preparations for human clinical study ➢ aap is in the process of intensive coordination with the competent authorities regarding scope and design of the human clinical study for the aimed CE and FDA approval ➢ Scope of the study still
Slide 11: Outlook FY/2018
Outlook FY/2018 FY/2018 ➢ Sales: EUR 13.0 million – EUR 15.0 million (FY/2017: EUR 10.9 million) ➢ EBITDA: EUR -5.0 million – EUR -3.4 million (FY/2017: EUR -6.2 million) Q1/2018 ➢ Sales: EUR 1.8 million – EUR 3.0 million (Q1/2017: EUR 3.1 million) ➢ EBITDA: EUR -1.9 million – EUR -1.4 million (Q1/2
Slide 12: Many thanks for your attention!
Many thanks for your attention! Lorenzweg 5 • 12099 Berlin • Germany Fabian Franke Manager Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de IR-app: 12